VAM
EPZM

Visium Asset Management’s Epizyme, Inc EPZM Stock Holding History

Visium Asset Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-28,166
Closed -$793K – 895
2013
Q2 		$793K Buy
+28,166
New +$724K 0.02% 391

Other funds holding EPZM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Visium Asset Management's EPZM Position: Q3 2013 in Review

Visium Asset Management sold out of Epizyme, Inc (EPZM) in Q3 2013, closing a stake of 28,166 shares — an estimated $793K sold.

Visium Asset Management first reported a position in EPZM in Q2 2013 and held it in 1 quarter. The position peaked at $793K in Q2 2013. 67 funds tracked by Wall St. Rank hold EPZM as of Q3 2013.

  • Visium Asset Management reported no remaining Epizyme, Inc position as of Q3 2013 after selling out during the quarter.
  • Visium Asset Management sold 28,166 Epizyme, Inc shares in Q3 2013, an estimated $793K.
  • Visium Asset Management first reported a position in Epizyme, Inc in Q2 2013 and held it in 1 quarter.
  • Visium Asset Management's Epizyme, Inc position peaked at $793K in Q2 2013.
  • 67 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2013.

Based on Visium Asset Management's 13F filing for Q3 2013, filed 14 Nov 2013.